# Pulmocide

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pulmocide

- Industry: Pharmaceuticals
- Headquarters: London, UK
- Website: www.pulmocide.com
- Total disclosed funding: $165M
- Latest round: Series C (Dec 6, 2022)
- Investors on record: 13

## About

Based in the UK, Pulmocide Limited focuses on developing innovative inhaled antifungal therapies designed to treat serious respiratory diseases, particularly invasive pulmonary aspergillosis.Pulmocide Limited, founded in 2013, is headquartered in London, UK, and specializes in developing antifungal treatments for respiratory diseases. The company has completed 6 deals, with its most recent funding round being a Series C in December 2022, raising USD 52.00 mn from investors including Adjuvant Capital and Johnson & Johnson Innovation. The company's lead product, opelconazole, is currently undergoing Phase 3 clinical trials. The founder's information is not disclosed in the provided data.Pulmocide primarily develops innovative inhaled antifungal therapies aimed at addressing serious respiratory diseases, with a particular focus on difficult-to-treat conditions such as invasive pulmonary aspergillosis. Its lead product, opelconazole, is designed to deliver high concentrations of the drug directly to the lungs, targeting fungal infections while minimizing systemic exposure. This investigational product is currently in a Phase 3 clinical trial and is intended for patients who do not respond adequately to standard antifungal treatments. Pulmocide's client base includes healthcare providers and institutions treating patients suffering from severe respiratory fungal infections, with products primarily marketed in the United States and European Union.In the most recent year, Pulmocide recorded no revenue, while the EBITDA for 2023 was reported at USD -46,557,461.80. The company generates revenue through partnerships and direct sales of opelconazole to healthcare institutions for the treatment of invasive pulmonary aspergillosis and related conditions, with pricing structured based on industry standards for innovative therapeutics.In December 2022, Pulmocide Limited raised USD 52.00 mn in Series C funding, co-led by Pictet Alternative Advisors and Vivo Capital. The company plans to utilize this funding for clinical development, preparing for the potential commercialization of opelconazole, and scaling up manufacturing. Pulmocide aims to expand its reach within the US and EU markets, targeting opportunities for new product launches and enhancements in treatment options for respiratory diseases.

## Funding rounds

- Series C, Dec 6, 2022, $52M — SR One, SV Health Investors, Johnson & Johnson Innovation, Vivo Capital, F-Prime Capital, Longview Innovation, Longwood Fund, Cystic Fibrosis Foundation, Pictet Alternative Advisors, Adjuvant Capital, Jeito Capital, Asahi Kasei Corporate Venture Capital
- Series C, May 17, 2021, $52M — SR One, SV Health Investors, F-Prime Capital
- Series B, Mar 17, 2017, $32M — SR One, SV Health Investors, Johnson & Johnson Innovation, F-Prime Capital, Longwood Fund, Touchstone Innovations
- Series A, Oct 31, 2013, $29M — SV Health Investors, Johnson & Johnson Innovation, F-Prime Capital, Touchstone Innovations

## Investors

- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series A, Series B, Series C
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A, Series B, Series C
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A, Series B, Series C
- Touchstone Innovations (https://capitalatlas.ai/funds/touchstone-innovations) — Series A, Series B
- SR One (https://capitalatlas.ai/funds/sr-one) — Series B, Series C
- Longwood Fund (https://capitalatlas.ai/funds/longwood-fund) — Series B, Series C
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series C
- Longview Innovation (https://capitalatlas.ai/funds/longview-innovation) — Series C
- Cystic Fibrosis Foundation — Series C
- Pictet Alternative Advisors (https://capitalatlas.ai/funds/pictet-alternative-advisors) — Series C
- Adjuvant Capital (https://capitalatlas.ai/funds/adjuvant-capital) — Series C
- Jeito Capital (https://capitalatlas.ai/funds/jeito-capital) — Series C
- Asahi Kasei Corporate Venture Capital — Series C